India’s Drug Regulator to Convene Industry Leaders Over Cough Syrup Safety Concerns
The move comes as part of a nationwide crackdown on substandard cough syrups, following international concerns regarding the presence of lethal impurities such as diethylene glycol (DEG) and ethylene glycol (EG).
- By Newsdesk
- New Delhi
- May 13, 2026
In an urgent bid to bolster the safety profile of Indian-made pharmaceuticals, the Central Drugs Standard Control Organization (CDSCO) has scheduled a high-level meeting with industry representatives to review the use of high-risk solvents in liquid medications.
The move comes as part of a nationwide crackdown on substandard cough syrups, following international concerns regarding the presence of lethal impurities such as diethylene glycol (DEG) and ethylene glycol (EG).
The upcoming deliberations will focus on tightening the quality control protocols for raw materials, specifically targeting the solvents used as carriers in syrups. Regulatory authorities are expected to mandate more rigorous testing for glycerin and propylene glycol, the two primary solvents often linked to contamination incidents. By enforcing stricter verification of the source and purity of these ingredients, the regulator aims to eliminate the risk of toxic chemicals entering the supply chain, which have previously led to catastrophic health outcomes in overseas markets.
Industry insiders suggest that the CDSCO may also introduce mandatory batch-wise testing for all syrup exports, ensuring that every consignment meets international safety benchmarks before leaving Indian shores. This proactive oversight is viewed as a critical step in restoring global confidence in the "Pharmacy of the World," particularly after the World Health Organization (WHO) issued several alerts involving Indian-manufactured liquid formulations over the past two years.
The meeting is also expected to address the modernization of manufacturing facilities, encouraging smaller pharmaceutical units to align with the revised Good Manufacturing Practices (GMP). As India targets 2026 as a milestone year for achieving near-total transparency in its drug manufacturing process, this regulatory intervention underscores the government’s zero-tolerance policy toward quality lapses. By bridging the gap between existing industrial standards and global safety expectations, the drug regulator seeks to safeguard public health while maintaining the competitive edge of India’s pharmaceutical exports.